Different viral rebound following discontinuation of antiretroviral therapy in cases of infection with viruses carrying L74V or thymidine-associated mutations.
A total of 76 patients discontinued treatment with didanosine plus hydroxyurea after 1 year of maintenance therapy. The greatest human immunodeficiency virus (HIV)-RNA rebounds were seen in 10 patients harboring an L74V mutation, and the presence of viruses with this mutation rapidly waned. In contrast, viral rebounds were significantly less pronounced (P < 0.01) in 12 subjects harboring thymidine-associated mutations; these mutations persisted in all instances. Thus, selection of an L74V mutation during didanosine therapy may compromise HIV replication in vivo.
de Mendoza
Carmen
C
Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain.
Paxinos
Ellen
E
Barreiro
Pablo
P
Camino
Nuria
N
Núñez
Marina
M
Soriano
Vincent
V
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology; D019943:Amino Acid Substitution; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D016049:Didanosine / Q000627:therapeutic use; D005260:Female; D005838:Genotype; D006678:HIV / Q000235:genetics*; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D008297:Male; D016297:Mutagenesis, Site-Directed; D009154:Mutation; D012367:RNA, Viral / Q000235:genetics / Q000302:isolation & purification; D013936:Thymidine / Q000235:genetics*; D013997:Time Factors; D019562:Viral Load
D019380:Anti-HIV Agents; D012367:RNA, Viral; D016049:Didanosine; D013936:Thymidine; D006918:Hydroxyurea